SMAD2 Cancer Research Results

SMAD2, SMAD family member 2: Click to Expand ⟱
Source: CGL-Driver Genes
Type: TSG
SMAD2 (SMAD family member 2) is a protein that plays a crucial role in the transforming growth factor-beta (TGF-β) signaling pathway, which is involved in various cellular processes, including cell growth, differentiation, and apoptosis.
In some cancers, SMAD2 functions as a tumor suppressor. TGF-β signaling can inhibit cell proliferation and promote apoptosis in normal and early-stage cancer cells. In this context, SMAD2 helps to mediate these effects, and its loss or mutation can contribute to tumor progression. Conversely, in advanced cancers, TGF-β signaling can promote tumor progression and metastasis. In these cases, SMAD2 may contribute to the epithelial-to-mesenchymal transition (EMT), a process that allows cancer cells to acquire migratory and invasive properties. This dual role can make targeting the TGF-β/SMAD2 pathway challenging in cancer therapy.
Nor, Normal Healthy: Click to Expand ⟱
Normal Healthy
Scientific Papers found: Click to Expand⟱
1173- Ash,    Withaferin A inhibits proliferation of human endometrial cancer cells via transforming growth factor-β (TGF-β) signalling
- in-vitro, EC, K1 - in-vitro, Nor, THESCs
TumCP↓, *toxicity↓, Apoptosis↑, TumCCA↑, TumCMig↓, TumCI↓, p‑SMAD2↓, TGF-β↓, *toxicity↓,
8086- KAE,    Hepatoprotective Effect of Kaempferol: A Review of the Dietary Sources, Bioavailability, Mechanisms of Action, and Safety
- Review, Nor, NA
*hepatoP↑, *BioAv↝, *CYP2E1↓, *antiOx↑, *AST↓, *ALAT↓, *ROS↓, *lipid-P↓, *SIRT1↑, *GSH↑, *SOD↑, *p‑SMAD2↓, *p‑SMAD3↓, *COL1↓, *other↝,
8080- KAE,    Hepatoprotective Effect of Kaempferol—A Review
- Review, Nor, NA
*hepatoP↑, *SIRT1↑, *AMPK↑, *TLR4↓, *NF-kB↓, *GutMicro↑, *Dose↝, *BioAv↓, *BioAv↑, *CYP2E1↓, *lipidLev↓, *COX2/PTGS2↓, *IL1β↓, *TNF-α↓, *IL6↓, *NO↓, *PGE2↓, *iNOS↓, *SOD↑, *MDA↓, *ROS↓, *AST↓, *ALAT↓, *GSH↑, *SOD↑, *Cyt‑c↓, *BAX↓, *Casp3↓, *Casp8↓, *Casp9↓, *COL1↓, *p‑SMAD2↓, *p‑SMAD3↑, *α-SMA↓, *TGF-β↓, *P450↝, *P-gp/ABCB1↓, *BioEnh↑,
1266- LE,    Glycyrrhizin suppresses epithelial-mesenchymal transition by inhibiting high-mobility group box1 via the TGF-β1/Smad2/3 pathway in lung epithelial cells
- in-vitro, Lung, A549 - in-vitro, Nor, BEAS-2B
HMGB1↓, EMT↓, TumCMig↓, p‑SMAD2↓, p‑SMAD3↓,
3478- MF,    One Month of Brief Weekly Magnetic Field Therapy Enhances the Anticancer Potential of Female Human Sera: Randomized Double-Blind Pilot Study
- Trial, BC, NA - in-vitro, BC, MCF7 - in-vitro, Nor, C2C12
TumCP↓, TumCMig↓, TumCI↓, *toxicity∅, TGF-β↓, Twist↓, Slug↓, β-catenin/ZEB1↓, Vim↓, p‑SMAD2↓, p‑SMAD3↓, angioG↓, VEGF↓, selectivity↑, LIF↑,
1133- SM,    Salvianolic Acid A, a Component of Salvia miltiorrhiza, Attenuates Endothelial-Mesenchymal Transition of HPAECs Induced by Hypoxia
- in-vitro, Nor, HPAECs
*ROS↓, *p‑Smad1↑, *p‑SMAD5↑, *SMAD2↓, *SMAD3↓, *p‑ERK↓, *p‑Cofilin↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

EMT↓, 1,  

Migration(tgid=13) ⓘ

Slug↓, 1,   p‑SMAD2↓, 3,   p‑SMAD3↓, 2,   TGF-β↓, 2,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 2,   Twist↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

HMGB1↓, 1,   LIF↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

selectivity↑, 1,  
Total Targets: 18

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   CYP2E1↓, 2,   GSH↑, 2,   lipid-P↓, 1,   MDA↓, 1,   ROS↓, 3,   SOD↑, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 2,   AMPK↑, 1,   lipidLev↓, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

BAX↓, 1,   Casp3↓, 1,   Casp8↓, 1,   Casp9↓, 1,   Cyt‑c↓, 1,   iNOS↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

p‑ERK↓, 1,  

Migration(tgid=13) ⓘ

p‑Cofilin↓, 1,   COL1↓, 2,   p‑Smad1↑, 1,   SMAD2↓, 1,   p‑SMAD2↓, 2,   SMAD3↓, 1,   p‑SMAD3↓, 1,   p‑SMAD3↑, 1,   p‑SMAD5↑, 1,   TGF-β↓, 1,   α-SMA↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1β↓, 1,   IL6↓, 1,   NF-kB↓, 1,   PGE2↓, 1,   TLR4↓, 1,   TNF-α↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   BioAv↝, 1,   BioEnh↑, 1,   Dose↝, 1,   P450↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 2,   AST↓, 2,   GutMicro↑, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↑, 2,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 52

Scientific Paper Hit Count for: SMAD2, SMAD family member 2
2 Kaempferol
1 Ashwagandha(Withaferin A)
1 Licorice
1 Magnetic Fields
1 Salvia miltiorrhiza
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:49  Cells:%  prod#:%  Target#:283  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page